Inflammatory bowel disease biomarkers

Med Res Rev. 2022 Sep;42(5):1856-1887. doi: 10.1002/med.21893.Epub 2022 May 23.


Dandan Liu 1Varma Saikam 1Katie A Skrada 1Didier Merlin 2 3Suri S Iyer 1


Author information

1Department of Chemistry, 788 Petit Science Center, Georgia State University, Atlanta, Georgia, USA.

2790 Petit Science Center, Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA.

3Atlanta Veterans Medical Center, Decatur, Georgia, USA.


Inflammatory bowel disease (IBD) is characterized as chronic inflammation in the gastrointestinal tract, which includes two main subtypes, Crohn's disease and ulcerative colitis. Endoscopy combined with biopsy is the most effective way to establish IBD diagnosis and disease management. Imaging techniques have also been developed to monitor IBD. Although effective, the methods are expensive and invasive, which leads to pain and discomfort. Alternative noninvasive biomarkers are being explored as tools for IBD prognosis and disease management. This review focuses on novel biomarkers that have emerged in recent years. These serological biomarkers and microRNAs could potentially be used for disease management in IBD, thereby decreasing patient discomfort and morbidity.

© Copyright 2013-2024 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.